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Abstract
Cystic fibrosis pulmonary disease is characterized by excessive and prolonged inflammation. CF 
Pulmonary disease severity exhibits considerable variation that, to some extent, appears to be due 
to the presence of modifier genes. Several components of the inflammatory response are known to 
have altered regulation in the CF lung. Genetic variants in 52 inflammatory genes were tested for 
associations with lung disease indices in a CF patient population (n=737) homozygous for the 
ΔF508 cystic fibrosis transmembrane conductance regulator mutation. Variants in 3 inflammatory 
genes showed significant genotypic associations with CF lung disease severity, including IL8 and 
previously reported TGFβ11 (p≤0.05). When analyzed by gender, it was apparent that IL8 variant 
associations were predominantly due to males. The IL8 variants were tested in an additional CF 
population (n=385) and the association in males verified (p≤0.01). The IL8 variants were in strong 
linkage disequilibrium with each other (R2≥0.82), while variants in neighboring genes CXCL6, 
RASSF6 and PF4V1 did not associate (p≥0.26) and were in weaker LD with each other and with 
the IL8 variants (0.01≤R2≤0.49). Studies revealed differential expression between the IL8 
promoter variant alleles (p<0.001). These results suggest that IL8 variants modify CF lung disease 
severity and have functional consequences.
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Cystic fibrosis (CF) is an autosomal recessive disease that is caused by mutations in cystic 
fibrosis transmembrane conductance regulator (CFTR)2. Although CF is considered to be a 
classic monogenic disease, there is considerable phenotypic variation in CF among patients 
that share the same CFTR mutations; this is especially true with regards to pulmonary 
disease progression.3 It has been suggested that the majority of the variation observed in 
pulmonary disease is due to genetic heterogeneity, independent of CFTR genotype4. Our 
previous work has revealed that transforming growth factor β1 (TGF-β1), which is involved 
in immune responses and contributes to the progression of lung disease in animals, is a 
genetic modifier of CF lung disease1; however, TGFβ1 is predicted to only account for a 
small amount of the disease variation.
CF pulmonary disease is characterized by persistent inflammation and recurrent infection.5 
Several components of the inflammatory response (chemokines, cytokines, transcription 
factors, etc.) are known to have altered expression in the CF lung.6–8 In general, 
dysregulation of the inflammatory responses is considered to be the primary source of much 
of the pathophysiology in CF.9–13 The gender of a patient may also contribute to this 
phenomenon, as females are reported to display worse lung disease than males, which is 
demonstrated by earlier colonization with P. aeruginosa14, reduced lung function14, and 
shorter lifespan14–16.
Here we report a survey of genetic variation in inflammatory pathway components, along 
with the effect of gender, and their effect on the severity of CF pulmonary disease. We 
selected 181 variants from a panel of 52 inflammatory genes and tested them for association 
with CF disease severity (see Supplementary Data). Common single nucleotide 
polymorphisms (SNPs) in these inflammatory genes were genotyped first in a large CF 
patient population (n=737) in which each subject is homozygous for the ΔF508 CFTR 
mutation, and associating variants then tested in a second cohort of 385 patients. Variants in 
the IL8 gene showed significant association with disease severity in males in both cohorts of 
CF patients. In vitro functional studies revealed differences in transcription due to the 
rs4073 IL8 promoter variant.
RESULTS
Inflammatory Gene Screen
One hundred eighty-one single nucleotide polymorphisms (SNPs) in 52 genes involved in 
inflammation were examined for skewing of genotype frequency between severely and 
mildly affected ΔF508-homozygous CF patients ascertained by lung disease status17. These 
52 genes were a subset of a larger project that included 810 variants in 300 gene regions, all 
selected as candidate modifiers of CF disease severity based on specific pathways thought to 
contribute to CF pathophysiology. Using a χ2 test of independence, genotype frequencies of 
49 of the 810 polymorphisms (6%) were significantly different between mild and severe 
patients (P < 0.05) while only 4 of the 181 inflammatory gene variants (2.2%) were 
significant. These 4 SNPs represented 4 different genes, including previously reported 
TGFB11, and therefore only the remaining 3 are included here, namely interleukin 8 (IL8), 
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interleukin 10 receptor B (IL10RB), and transforming growth factor beta-induced protein 
(TGFBI).
In addition to the test of independence, the cohort was assessed for possible population 
stratification using a genome control method (see Methods). The values of λ ranged from 
1.0 to 1.29, suggesting stratification is minimal in this population and the adjusted p values 
are given for genotypes in Table 1.
Defining the associating interval
Alleles of 4 of the 52 inflammation-related genes tested showed significant associations with 
lung disease severity (p<0.05). Of the newly reported associations, IL8 was selected for 
further characterization because its variants have been reported to associate with 
susceptibility to other airway disorders18, 19. Additionally, IL-8 is an integral component of 
CF lung disease; it is elevated, with substantial variation, in the lungs of CF patients6, 20. 
Because of the reported genetic association with CF lung function and the biological 
plausibility of IL8 as a genetic modifier of CF airway pathophysiology, the IL8 genomic 
region was investigated in more detail.
The strategy employed was to first define the genetic interval with the most significant 
association and evaluate the candidate interval in a second group of patients. To this end, we 
first examined markers in genes neighboring IL8 to determine which interval contained the 
most significant association. As IL8 is in proximity to several other chemokine genes in the 
chromosome 4q12–q13 region, and work by others suggests that some of these genes may 
be in linkage disequilibrium (LD) with IL821, one could not rule out flanking genes as the 
source of association in our initial screen.
There are 13 known CXC-family chemokine genes in the human genome, apparently the 
result of gene duplication22. Eight of these genes are in the IL8 genomic region (4q13–21), 
therefore functional redundancy is of concern. Guided by the findings of Hull et. al. showing 
three distinct LD blocks (r2>0.3) encompassing IL8 and the genes immediately flanking 
it.23, we selected the following variants for further evaluation: rs13131954 from RASSF6 
and rs941758 from PF4V1 to represent the LD blocks adjacent to IL823 and rs4694639 from 
CXCL6, which is immediately 3′ of IL8, but for which the LD relationship has not been 
reported. The arrangement of these genes and the location of markers is shown in Figure 1. 
The pairwise linkage disequilibrium pattern was determined for all eight markers. The four 
IL8 markers were all in strong LD (R2>0.82, Table 2). The CXCL6 marker is in moderate 
LD with the IL8 markers (0.39≤R2≤0.47), but the RASSF6 and PF4V1 markers are 
essentially in equilibrium with IL8 and CXCL6 (R2≤0.16). Our data are concordant with 
those of Hull23 and show that not only are the IL8 markers in very strong LD with each 
other, but also that the CXCL6 marker is in modest LD with the IL8 alleles (Table 2).
The markers across this region (240 kb) were tested for association with the lung disease 
phenotypes, severe and mild (see Methods), and the most significant associations were 
restricted to those markers in the IL8 gene (Table 3). There was no significant association 
between the RASSF6 (p=0.25), CXCL6 (p=0.26), or PF4V1 (p=0.29) markers and lung 
function. These analyses indicate that the most significant markers are those in high linkage 
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disequilibrium with each other, and corresponding to the IL8 gene, strongly implicating only 
the IL8 interval.
Because of the differences in pulmonary disease observed between males and females, we 
assessed males and females separately. Table 4 shows that the most significant findings are 
found in the male sub-population and do not extend outside of the IL8 markers (Table 3).
Testing the association in additional populations
As Table 4 indicates, the evidence for association is more significant in the males than 
females, but is modest even in males. Therefore, an additional population was examined to 
determine if the association, particularly in males, could be replicated. Three of the IL8 
markers were typed in a second cohort. Patients in Cohort 2 (n=385, 219 males) were 
ascertained by the same phenotypic criteria as Cohort 1, but were not all homozygous for the 
ΔF508 mutation. They did, however, carry at least one copy of the ∆F508 CFTR mutation 
and another pancreatic insufficiency-associated mutation24 on the second allele. As Table 5 
shows, the males in these two cohorts are not significantly different across indices of 
pulmonary function.
Males and females in Cohort 2 were assessed separately using a χ2 test of association. In 
accordance with the first population, only male genotypes showed significant associations 
(0.01>p>0.08) in this second cohort (Table 4). The reproducibility of the association only in 
males indicates that gender is a major factor in IL8’s role as a genetic modifier of CF. We 
also examined the IL8 SNPs for departures from Hardy-Weinberg proportions and found no 
evidence of such departures in either of the cohorts, nor in males alone (P > 0.6).
The IL8 markers display high LD with each other and are therefore largely redundant in 
their information. An example of the genotype distribution in the studied subjects is 
provided for the promoter polymorphism A-251T (rs4073) in Table 6. The frequency of 
males homozygous for the A allele in the mild group is greater than in the severe group 
(25.6% vs. 18.9%), while the frequency of T homozygotes is greater for the male subjects in 
the severe group (38.9% vs. 25.1%). Heterozygosity is found more often in the mildly 
affected males (49.3% vs. 42.1%), suggesting a dominant or semi-dominant effect of the A 
allele on the mild phenotype.
Effect of other loci and phenotypes on IL8 association
We previously reported an association between variants in the transforming growth factor-
β1 gene, TGFB1, and pulmonary function. Logistic regression was used to determine if there 
were evidence of interaction between these two genes, Using the TGFB1 promoter and 
codon 10 polymorphisms, no significant interactions were identified with any of the 4 IL8 
variants (0.96 > P > 0.46).
To determine if the association found in males might be reflective of other pulmonary 
conditions, the incidence of physician-reported asthma was assessed by genotype as well 
and was not significant (0.05 < P <0.4).
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Effect of the IL8 promoter variant on expression
A significant statistical association between IL8 gene polymorphisms and CF pulmonary 
disease has been demonstrated in two populations; however these associations do not 
address the functional mechanism by which these variants modify phenotype.
A luciferase-reporter assay was used to assess the IL8 promoter variant for effects at the 
level of transcription. IL8 promoter-luciferase constructs with either the A or T allele at 
variant rs4073 (rs4073A or rs4073T) were transiently transfected into 9HTEo− cells 
(pCEP-2), treated with a pro-inflammatory cytokine mix, and luciferase output measured at 
6, 12, and 24 hours post-treatment.
Treatment with the cytokine mix induced a significant increase in luciferase expression for 
both constructs (p<0.001) (Figure 2A), but under all conditions the T allele expressed 2–3 
times more than the A allele (p<0.001) (Figure 2B). The fold induction of both constructs by 
the cytokine mix was similar and non-significant, however (p>0.56, data not shown).
DISCUSSION
Pulmonary disease in CF, which is characterized by recurrent infections and excessive 
inflammation5, 12, exhibits marked phenotypic variability, due in part to genetic variation, or 
so-called modifier genes.25–27 In general, a dysregulation of inflammatory responses (with 
an overall increase in pro-inflammatory and decrease in anti-inflammatory response) is 
thought to be a key contributor to the lung pathophysiology in CF10, 11. Due to the central 
role of inflammation in the lung, we attempted to determine whether variants in 
inflammatory genes could act as modifiers of CF lung disease.
A panel of polymorphisms in candidate inflammatory genes (n=52) thought to be relevant to 
cystic fibrosis (CF), as determined through a literature review, were screened for 
associations with level of lung function in a cohort of CF patients (n=737). Polymorphisms 
in three inflammatory pathway genes showed nominal associations in the initial survey: 
IL10 receptor (IL10R), TGFβ-induced protein (TGFβI), and interleukin-8 (IL8). IL8 was 
selected for further characterization because its variants have been reported to associate with 
susceptibility to other airway disorders18, 19. Additionally, IL-8 is an integral component of 
CF lung disease; it is elevated, with substantial variation, in the lungs of CF patients6, 20. 
The primary function of IL-8 is to mediate neutrophil chemotaxis, and CF lung 
inflammation is largely characterized by neutrophilic infiltrates, leading to subsequent tissue 
damage28–31. Thus, the role of IL8 polymorphisms in CF pathophysiology should be more 
readily understood than that of the other candidates.
Our studies found that three polymorphisms within IL8 associate with CF pulmonary disease 
severity, rs4073, rs2227306 and rs2227307, and the effect was most obvious in males. With 
respect to pulmonary phenotype, associations between the rs4073 variant and infant 
susceptibility to bronchiolitis subsequent to infection with respiratory syncytial virus 
(RSV)18, 32 and bronchial asthma19 have been identified. The studies by Hull and Hacking 
found that homozygosity for the rs4073A allele is associated with increased occurrence of 
bronchiolitis following acute RSV infection, while the rs4073T allele is protective against 
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this condition18, 32. In our CF groups, we find that the rs4073A allele is protective and the 
rs4073T allele is associated with the more severe phenotype. A similar finding was reported 
in a study in which the rs4073T allele was associated with bronchial asthma, which is a 
chronic pulmonary condition19. That the same variant seems to have contradicting 
associations suggests that the functional impact of this variant is context dependent. We 
propose that the context of inflammation (i.e., acute as in innate defense versus chronic 
stimulation) may dictate the direction of the association.
The reason for the observed gender effect is not clear but a phenomenon that is not novel in 
CF. Females with CF have an overall worse prognosis as demonstrated by earlier 
colonization with P. aeruginosa14, reduced lung function14, and more rapid decline than 
males, suggesting that the inflammatory burden is greater in the female lung than the 
male14, 15, 34–36 and culminating in shorter lifespan14–16 for females. Sex hormones are able 
to regulate cytokine expression33, but there is no evidence that IL8 expression is directly 
regulated by sex hormones or that there are no known sex hormone-responsive elements in 
the IL8 promoter. Thus, the sex-specific association is likely more complicated than 
hormone-responsive transcription. Whether our results reflect an ascertainment bias due to 
our study design (selecting males and females using the same criteria for both may impose a 
bias) or a true sex-specific effect could be addressed by replication in populations without 
exclusion of intermediate phenotypes. In the populations studied here, the relative risk of 
having severe lung disease for patients homozygous for the “severe” allele of rs4073 is 1.7 
(p=0.04) but increases to 2.25 when considering only males (P=0.001).
As there are no known common variants in the coding sequence one of IL8, variation is 
most likely due to quantitative effects. Two of the variants are located in introns (rs2227307 
and rs2227543) while the remaining variant (rs4073) is found in the promoter region of IL8 
and has been shown to associate with several pulmonary phenotypes18, 19, 32 and to have 
demonstrated functional effects18, 32. We therefore felt this variant to be the most likely 
candidate to impart the functional effect and rs4073 was therefore the target for functional 
testing. We found that the rs4073T variant induces a 2–3 fold increase in transcriptional 
activity relative to the rs4073A allele. Although such a modest fold change may not be 
usually considered biologically significant, context must be considered when investigating 
genetic modifiers of disease. As stated, CF patients are known to have abnormally high 
levels of IL-8 in their lungs6, 20. Given a scenario in which elevated IL-8 is associated with 
severe pulmonary disease, it is entirely plausible that a moderate, yet significant, and 
chronic increase in IL-8 could account for more severe lung disease. Based on our findings, 
we propose that regardless of colonization or exacerbation status, CF patients with the 
rs4073T allele have higher levels of IL8 expression and are thus more likely to have severe 
pulmonary disease.
Interpretation of previous evidence regarding IL8 transcript regulation is somewhat unclear. 
Hacking et. al.32 found that when assessed in basal and TNF-α stimulated reporter 
constructs, the T allele at −251 (rs4073T), which was predominant in our severe phenotypic 
groups, has more than twice the promoter activity of the A allele, which is similar to our 
findings32. However, when endogenous transcript levels are compared in primary epithelial 
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cells, the TNF-α stimulation results in marginally higher levels from the haplotype 
containing the A allele32.
Our reporter construct assays are in accord with similar studies, but we have not yet assessed 
endogenous transcript levels. Sequence analysis suggests the rs4073 variant alters binding 
for the Oct-1 transcription factor, which has been shown to regulate the expression of 
several cytokines37, 38 including IL832, 39. The IL8 variants do appear to alter expression 
levels, but mechanism of the regulation may be context dependent and will be explored in 
the future.
Other studies have identified potential genetic modifiers of CF; Hull et. al. showed variants 
in tumor necrosis factor-α (TNF-α) associate with FEV1 in CF patients,40–43 although we 
have not been able to replicate these findings in a larger group of subjects1. We have, 
however, found that variants within the transforming growth factor-β1 (TGF-β1) gene 
correlate with CF patient disease severity1. The findings presented here show that variants in 
IL8 associate reproducibly with lung disease severity in males with cystic fibrosis and that 
there is functional variation associated with one of the polymorphism. Taken in context with 
the biological role of IL-8, this gene likely modifies lung function in CF through different 
levels of neutrophil chemotaxis and subsequent differences in destruction of lung tissue.
METHODS
Patient Recruitment
The initial study cohort was made up of 737 CF patients enrolled in the Gene Modifier 
Study (GMS), ascertained by methods described previously1, 17. Briefly: All study subjects 
in cohort 1 are CF patients homozygous for the ΔF508 CFTR mutation. Based on data 
obtained from the National CF Patient Registry, upper and lower quartiles of lung function 
for age were determined. Using these values as a guide, subjects were designated as “mild” 
(n=491) or “severe” (n=246), respectively, to reflect their lung function profile. A case-
control study design was used to compare these groups, with patients with severe lung 
disease arbitrarily set as the case population and the mild group as the control population.
A second cohort ascertained for the same clinical criteria as the first, but including ΔF508 
compound heterozygous patients, were used for the replication study (n=385). Cohort 2 
patients not homozygous for ΔF508 carry one copy of the ΔF508 CFTR mutation and a 
mutation recognized as severe on the second allele, with severe defined as being associated 
with pancreatic exocrine insufficiency1. The same criteria for “mild” and “severe” used for 
cohort 1 were applied to the second cohort.
Both cohorts were assessed for indices of pulmonary function, including average forced 
expiratory volume in 1 second (FEV1), rate of decline in FEV1 and predicted FEV1 at age 
20 (EBint2017), as well as bacterial colonization and body mass index.
Genotyping
In the initial screen, genotyping was performed by SNP BeadArray™ (Illumina, 
Incorporated, San Diego, CA) technology and included the following polymorphic loci 
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within IL8 (position relative to the transcriptional start site, number of patients genotyped): 
rs4073 (A-251T, n=733), rs2227307 (G396T, n=732), and rs2227543 (T1632C, n=737). 
Patients not genotyped by Illumina, Inc. were genotyped at the following IL8 loci using 
restriction fragment length polymorphism (RFLP) assays. Primers and restriction enzymes 
used for the RFLP genotyping were (SNP, forward, reverse, product size, restriction 
endonuclease): rs4073, 5′-TGAAAAGTTGTAGTATGCCCC-3′, 5′-
CATTTAAAATACTGAAGCTCCACAATTTGGTGAATTATCgA-3′, 310 bp, ClaI; and 
rs2227543, 5′-
TGGTTAAAAAAAAAGGAATAGCATCAATAGTGAGTTTGTTGTcCT-3′, 5′-
ACCCTACAACAGACCCACACAATA-3′, 420 bp, MnlI. Lower case letters indicate a 
sequence change in order to introduce a restriction endonuclease recognition site. Digestion 
products were analyzed on a 2% agarose gel. Reactions were performed using Invitrogen 
Platinum Taq polymerase enzyme, 10× buffer, deoxyribonucleotides (2.5mM), and MgCl2 
(25mM). Annealing temperature, MgCl2 concentration, and amplification cycles were 
optimized for each primer set.
Variants in the RASSF6 (rs13131954, n=717), IL8 (rs2227306, n=727), CXCL6 (rs4694639, 
n=709), and PF4VI (rs941758, n=716) genes were genotyped using an Assay-on-Demand™ 
assay (Applied Biosystems, Foster City, CA).
Statistical Analysis
The distribution of the marker alleles and genotypes in the severe group was compared to 
that in the mild group using a chi-square test of independence. A goodness of fit test for 
Hardy-Weinberg Equilibrium (HWE) was performed by comparing the genotype 
frequencies with those expected on the basis of the observed allele frequencies44. SNPs with 
a p<0.05 for the test of HWE were noted as possibly requiring careful consideration of the 
possible causes of departure from HWE, but were not removed from the analysis. The IL8 
and flanking polymorphisms were found to exist in HWE, 0.27<p<0.96. All analyses were 
conducted in SPlus version X.0 (Insightful Corporation, Seattle, WA).
Population stratification
The current study was part of a larger project in which 737 subjects were typed for 810 
markers. The genomic control method45 was performed using these markers to examine the 
potential impact of population structure in this study. The observed values of the inflation 
factor λ ranged from 1 to 1.29, and were used to adjust the p-values of the IL-8 regional 
markers.
Pairwise Linkage Disequilibrium (LD)
The pattern of pairwise LD between SNPs was measured by the correlation coefficient 
(R2)46. R2 varies from 0 to 1 and measures the correlation between alleles on the same 
chromosome. R2 will take the value of 1 when the allele at one locus can always be 
predicted by the allele at the second locus (that is, if only two haplotypes are present).
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IL8 Promoter Luciferase Assay
The IL8 promoter (1.5kb) was cloned into a pGL3 vector (Promega Corporation, Madison, 
Wisconsin) containing the firefly luciferase gene. Using site-directed mutagenesis, two 
versions of the construct were generated to reflect the polymorphism at the −251 position 
(relative to the start of transcription), corresponding to SNP rs4073. The constructs are 
designated −251A/rs4073A and −251T/rs4073T.
These constructs were transiently co-transfected with the Renilla luciferase reporter 
construct (Promega) into control (pCEP-2) and CF-like (pCEP-RF) 9HTEo- cell lines47 
using FuGene 6 Transfection Reagent (Roche Applied Science, Indianapolis, Indiana). As 
results from the pCEP-2 and pCEP-RF cells lines were similar, only data from pCEP-2 cells 
are shown.
To induce IL8-promoter driven luciferase expression48, transfected cells were treated with 
physiologically relevant49 quantities of a pro-inflammatory cytokine mixture (interleukin-1β 
[0.167 ng/μl] and tumor necrosis factor-α [0.33 ng/μl]) in serum-free culture media 24 hours 
after transfection. Treatment with the cytokine mix was intended to mimic the pro-
inflammatory state in CF airway in which there are increased levels of IL-1β and TNF-α, 
both of which are considered key pro-inflammatory cytokines. Cells were also treated with 
hydrogen peroxide (H2O2), as oxidative stress has been shown promote inflammation50, 
which yielded a similar expression pattern to cytokine mix treatment (data not shown). 
Control cells were not exposed to stimulus, but rather to the phosphate-buffered saline 
diluent.
Cell lysates were harvested using the Dual-Luciferase Kit (Promega) at 6, 12, 24, 36 and 48, 
60, and 72 hours after treatment and luciferase activity measured in a luminometer (Turner 
BioSystems, Sunnyvale, California). All samples returned to baseline by 24 hours and thus 
data are shown for 6, 12, and 24 hour time points only. The average relative luminescence 
was obtained for each condition (n=30 wells). Comparisons were made between treated and 
untreated cells, as well as between alleles. In all cases comparisons were assessed by a two-
tailed, student’s t-test.
The cytokine mix was found to significantly repress Renilla expression (p<0.04 – p<0.005), 
thereby falsely inflating the magnitude of the observed response to the cytokine mix. 
Therefore, Renilla expression was only used to determine if transfection efficiencies were 
comparable for each time point. While expression estimates from the control samples were 
normalized to the co-transfected Renilla construct, the level of expression from the treated 
samples was not. Rather, multiple replicates were performed to ensure accuracy (30 
individually transfected wells for each condition).
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The surveyed IL8 genomic region (240 kb). Markers in the three genes most proximal to IL8 
were tested for an association with pulmonary disease severity. Arrows indicate direction of 
gene transcription. Solid black bars denote haplotype blocks as defined by the Haplotype 
Map Project34.
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pCEP-2 cells transfected with IL8 promoter-luciferase constructs (rs4073A or rs4073T) 
were treated with a pro-inflammatory cytokine mix. (a) Luciferase expression at 6, 12, and 
24 hours post-treatment. Treatment with the cytokine mix induced a significant increase in 
luciferase expression for both constructs, (b) Values represent relative luciferase activity of 
the rs4073T allele to the rs4073A allele (*p=0.08 p=, **p=0.01, all others p<0.0001).
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Table 1
Significantly associating SNPs in the initial inflammatory gene screen
Gene SNP n Genotypic p-value
IL8 rs2227307 732 0.04
IL10RB rs1467845 733 0.04
TGFBI rs248158 657 0.04
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Table 3
Analysis of association testing for SNPs in IL8-flanking genes
Gene SNP n Genotypic p-value






CXCL6 rs4694639 709 0.27
PF4V1 rs941758 716 0.40
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Table 4
Comparison of rs4073 genotypic p-values between cohort 1 and 2 reveals gender effect
rs4073 rs2227307 rs2227306 rs2227543
Patient Cohort 1:
 Total (n=737) 0.07 0.04 0.19 0.06
 Males (n=392) 0.07 0.06 0.15 0.12
 Females (n=345) 0.25 0.12 0.36 0.19
Patient Cohort 2:
 Total (n=385) 0.25 0.15 0.18 0.52
 Males (n=219) 0.01 0.08 0.01 0.06
 Females (n=166) 0.82 0.59 0.84 0.70
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Table 5
Clinical characteristics of Study Cohorts
Variable
Severe Males Mild Males
Cohort 1 (n=130) Cohort 2 (n=69) Cohort 1 (n=303) Cohort 2 (n=151)
Age – Mean (± SD) (yrs) 16.3 ± 4.5 17.1 ± 5.1 29.7 ± 9.9 31.5 ± 10.3
Age – Range (yrs) 8.1–32 8–25.9 15.1–54.1 15.1–58.2
FEV1 (± SD) (% predicted) 47.0 ± 17.1 46.5 ± 17.8 69.8 ± 30.0 64.0 ± 29.9
FEV1 (± SD) (decline %/year) −3.59 ± 2.27 −3.63 ± 2.01 −1.41 ± 1.52 −1.30 ± 1.59
EBint20 (± SD) 34.5 ± 17.4 35.0 ± 17.3 84.8 ± 15.3 82.0 ± 17.0
Body mass Index (± SD) (percentile) 17.5 ± 2.05 17.8 ± 2.80 22.4 ± 2.76 22.4 ± 2.78
P. aeruginosa Positive (%) 85.4 85.7 85.8 90.4
% ΔF508/ΔF508 100.0 63.0 100.0 66.7
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Table 6
Comparison of rs4073 genotypes between cohort 1 and 2 reveals gender effect
%AA %AT %TT Genotypic p-value
Patient Cohort 1:
 All (n=733):
  Mild (n=490) 25.6 48.8 25.6
0.07
  Severe (n=243) 19.2 50.8 30.0
 Males (n=389):
  Mild (n=271) 26.5 50.0 23.5
0.07
  Severe (n=118) 19.5 46.9 33.6
Patient Cohort 2:
 All (n=379): 22.7 46.7 30.6
0.25  Mild (n=242) 20.4 42.3 37.2
  Severe (n=137)
 Males (n=219):
  Mild (n=149) 23.6 47.9 28.6
0.01
  Severe (n=70) 17.5 33.3 49.2
Patient Cohorts 1 and 2:
 All(n=l 112):
  Mild (n=732) 24.7 48.2 27.1
0.02
  Severe (n=380) 19.6 47.9 32.5
 Males (n=608):
  Mild (n=420) 25.6 49.3 25.1
0.001
  Severe (n= 18 8) 18.9 42.1 38.9
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